Incidence and causes of death in HIV‐infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area
- 24 April 2007
- journal article
- research article
- Published by Wiley in HIV Medicine
- Vol. 8 (4) , 251-258
- https://doi.org/10.1111/j.1468-1293.2007.00468.x
Abstract
Background: Since the introduction of highly active antiretroviral therapy (HAART), the incidence of death in HIV‐infected patients has dramatically decreased, and causes of death other than those related to HIV infection have increased, although it is unclear how these parameters compare with those in the age‐matched general population living in the same geographical region.Methods: Consecutive HIV‐infected adults who were prescribed HAART in our hospital were prospectively followed from January 1997 to December 2004 or until death, loss to follow‐up or discontinuation of HAART. Estimations of the annual incidence and causes of death in the general population of similar age in Catalonia per calendar year in the study period were obtained and compared with those in the HIV‐infected cohort.Results: There were 235 deaths among the 4471 patients on HAART (5%). The incidence of mortality decreased over time in HIV‐infected patients (P2 test for trend), although it has remained approximately five times higher than that for the age‐matched general population. AIDS‐related events were the most common cause of death (n=95; 40%), although they significantly decreased over time (P2 test for trend), whereas liver diseases (P2 test for trend) and non‐AIDS‐defining infections (P=0.008; χ2 test for trend) significantly increased over time. Infections in general (33 times higher), liver diseases (11 times higher) and non‐Hodgkin lymphoma (5 times higher) were overrepresented as causes of death in the HIV‐infected cohort compared with the age‐matched general population.Conclusions: Non‐AIDS‐defining infectious diseases, liver diseases, and non‐Hodgkin lymphoma represent specific targets for efforts to further decrease mortality in HIV‐infected patients receiving HAART.Keywords
This publication has 27 references indexed in Scilit:
- Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British ColumbiaAIDS, 2006
- Survival and progression to AIDS in a seroconverter cohort in the post-highly active antiretroviral therapy era: effectiveness goes onAIDS, 2006
- Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?AIDS, 2005
- AIDS events among individuals initiating HAART: do some patients experience a greater benefit from HAART than others?AIDS, 2005
- Changing mortality rates and causes of death for HIV‐infected individuals living in Southern Alberta, Canada from 1984 to 2003HIV Medicine, 2005
- Causes of death in HIV infectionAIDS, 2004
- Mortality in HIV‐Seropositive versus ‐Seronegative Persons in the Era of Highly Active Antiretroviral Therapy: Implications for When to Initiate TherapyThe Journal of Infectious Diseases, 2004
- Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDSInternational Journal of Epidemiology, 2004
- Trends in Causes of Death among Persons with Acquired Immunodeficiency Syndrome in the Era of Highly Active Antiretroviral Therapy, San Francisco, 1994–1998The Journal of Infectious Diseases, 2002
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998